C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center
Advertisement
C. Ola Landgren, MD, PhD, is a professor of medicine and chief of the Division of Myeloma in the Department of Medicine at the University of Miami Miller School of Medicine; director of the Sylvester Myeloma Institute; and co-leader of the Translational and Clinical Oncology Program and Paul J. DiMare Endowed Chair in immunotherapy at the Sylvester Comprehensive Cancer Center.
Articles by Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center
C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.
C. Ola Landgren, MD, PhD, discusses the utility of minimal residual disease as an end point in clinical trials for the treatment of multiple myeloma.
Advertisement
Latest Updated Articles
Updates in Multiple Myeloma in the Frontline SettingPublished: January 29th 2021 | Updated:
Updates in Relapsed/Refractory MyelomaPublished: January 29th 2021 | Updated:
Third and Subsequent Line Options for Multiple MyelomaPublished: January 29th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5